Safety of Certolizumab Pegol in Chronic Plaque Psoriasis: Cumulative Data Over 48 Weeks’ Exposure from Phase 3, Multicenter, Randomized, Placebo-Controlled Studies. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 2, n. S1, p. S16, 2018. DOI: 10.25251/skin.2.supp.16. Disponível em: https://skin.dermsquared.com/skin/article/view/307. Acesso em: 19 apr. 2025.